Revisiting Beta-Blocker Therapy in Heart Failure with Preserved Ejection Fraction
<p dir="ltr">Heart failure with preserved ejection fraction (HFpEF) is a heterogenous disorder and tends to be predominant in elderly, female, and obese patients. HFpEF has been classified using various cut-offs of left ventricular ejection fraction in the published studies with a cu...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | |
| منشور في: |
2023
|
| الموضوعات: | |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1864513561770852352 |
|---|---|
| author | Rasha Kaddoura (12506936) |
| author2 | Ashfaq Patel (16855122) |
| author2_role | author |
| author_facet | Rasha Kaddoura (12506936) Ashfaq Patel (16855122) |
| author_role | author |
| dc.creator.none.fl_str_mv | Rasha Kaddoura (12506936) Ashfaq Patel (16855122) |
| dc.date.none.fl_str_mv | 2023-12-01T00:00:00Z |
| dc.identifier.none.fl_str_mv | 10.1016/j.cpcardiol.2023.102015 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/Revisiting_Beta-Blocker_Therapy_in_Heart_Failure_with_Preserved_Ejection_Fraction/23994624 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biomedical and clinical sciences Cardiovascular medicine and haematology Beta-Blocker Therapy Heart Failure Preserved Ejection Fraction |
| dc.title.none.fl_str_mv | Revisiting Beta-Blocker Therapy in Heart Failure with Preserved Ejection Fraction |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <p dir="ltr">Heart failure with preserved ejection fraction (HFpEF) is a heterogenous disorder and tends to be predominant in elderly, female, and obese patients. HFpEF has been classified using various cut-offs of left ventricular ejection fraction in the published studies with a current cut-off of ≥50%. The evidence of beta-blocker therapy in HFpEF patients showed conflicting findings with variably reported efficacy. This review aims to examine the published studies on the use of beta blockers for the treatment of patients with HFpEF.</p><h3>Other Information</h3><p dir="ltr">Published in: Current Problems in Cardiology<br>License: <a href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1016/j.cpcardiol.2023.102015" target="_blank">https://dx.doi.org/10.1016/j.cpcardiol.2023.102015</a></p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_1201cb635f8ddca414d0fe1fc8cf0a20 |
| identifier_str_mv | 10.1016/j.cpcardiol.2023.102015 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/23994624 |
| publishDate | 2023 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Revisiting Beta-Blocker Therapy in Heart Failure with Preserved Ejection FractionRasha Kaddoura (12506936)Ashfaq Patel (16855122)Biomedical and clinical sciencesCardiovascular medicine and haematologyBeta-BlockerTherapyHeart FailurePreserved Ejection Fraction<p dir="ltr">Heart failure with preserved ejection fraction (HFpEF) is a heterogenous disorder and tends to be predominant in elderly, female, and obese patients. HFpEF has been classified using various cut-offs of left ventricular ejection fraction in the published studies with a current cut-off of ≥50%. The evidence of beta-blocker therapy in HFpEF patients showed conflicting findings with variably reported efficacy. This review aims to examine the published studies on the use of beta blockers for the treatment of patients with HFpEF.</p><h3>Other Information</h3><p dir="ltr">Published in: Current Problems in Cardiology<br>License: <a href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1016/j.cpcardiol.2023.102015" target="_blank">https://dx.doi.org/10.1016/j.cpcardiol.2023.102015</a></p>2023-12-01T00:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1016/j.cpcardiol.2023.102015https://figshare.com/articles/journal_contribution/Revisiting_Beta-Blocker_Therapy_in_Heart_Failure_with_Preserved_Ejection_Fraction/23994624CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/239946242023-12-01T00:00:00Z |
| spellingShingle | Revisiting Beta-Blocker Therapy in Heart Failure with Preserved Ejection Fraction Rasha Kaddoura (12506936) Biomedical and clinical sciences Cardiovascular medicine and haematology Beta-Blocker Therapy Heart Failure Preserved Ejection Fraction |
| status_str | publishedVersion |
| title | Revisiting Beta-Blocker Therapy in Heart Failure with Preserved Ejection Fraction |
| title_full | Revisiting Beta-Blocker Therapy in Heart Failure with Preserved Ejection Fraction |
| title_fullStr | Revisiting Beta-Blocker Therapy in Heart Failure with Preserved Ejection Fraction |
| title_full_unstemmed | Revisiting Beta-Blocker Therapy in Heart Failure with Preserved Ejection Fraction |
| title_short | Revisiting Beta-Blocker Therapy in Heart Failure with Preserved Ejection Fraction |
| title_sort | Revisiting Beta-Blocker Therapy in Heart Failure with Preserved Ejection Fraction |
| topic | Biomedical and clinical sciences Cardiovascular medicine and haematology Beta-Blocker Therapy Heart Failure Preserved Ejection Fraction |